These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19344195)

  • 21. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes.
    Jackson A; Ternand C; Brunzell C; Kleinschmidt T; Dew D; Milla C; Moran A
    Pediatr Diabetes; 2003 Jun; 4(2):64-9. PubMed ID: 14655261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous glucose monitoring pilot in low-income type 1 diabetes patients.
    Sequeira PA; Montoya L; Ruelas V; Xing D; Chen V; Beck R; Peters AL
    Diabetes Technol Ther; 2013 Oct; 15(10):855-8. PubMed ID: 23865840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL
    Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.
    Retnakaran R; Hochman J; DeVries JH; Hanaire-Broutin H; Heine RJ; Melki V; Zinman B
    Diabetes Care; 2004 Nov; 27(11):2590-6. PubMed ID: 15504991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.
    Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW
    Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
    Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
    Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
    Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial.
    Laffel LM; Hsu WC; McGill JB; Meneghini L; Volkening LK
    Diabetes Technol Ther; 2007 Jun; 9(3):254-64. PubMed ID: 17561796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
    Rosenstock J; Eliaschewitz FG; Heilmann CR; Muchmore DB; Hayes RP; Belin RM
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S63-73. PubMed ID: 19772451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.
    Bevier WC; Castorino KN; Axelrod C; Haroush G; Farfan CC; Shelton N; Nelson K; Spink LA; Liu H; Kerr D
    Diabetes Care; 2022 Jan; 45(1):67-73. PubMed ID: 34716211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
    Zinman B; Philis-Tsimikas A; Cariou B; Handelsman Y; Rodbard HW; Johansen T; Endahl L; Mathieu C;
    Diabetes Care; 2012 Dec; 35(12):2464-71. PubMed ID: 23043166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.